Company Overview of Les Laboratoires Servier SAS
Les Laboratoires Servier SAS, a pharmaceutical company, engages in the research and development of reference products to treat various diseases primarily in France. It also produces drugs for clinical trials in cardiovascular disease, endocrinology, oncology, rheumatology, venous disease, ENT, neurosciences, and asthenia product portfolio. Les Laboratoires Servier SAS has a strategic alliance with Galapagos NV; strategic collaboration agreement with Cellectis SA; and strategic partnership with Intarcia Therapeutics, Inc., as well as GeNeuro SA. The company was founded in 1954 and is based in Neuilly Sur Seine, France with operations in the United States, Australia, Canada, China, and the Rus...
22 Rue Garnier
Neuilly Sur Seine, 92578
Founded in 1954
Key Executives for Les Laboratoires Servier SAS
Manager of Northern Asia Operations
Compensation as of Fiscal Year 2014.
Les Laboratoires Servier SAS Key Developments
Hybrigenics Extends Partnership with Servier for USPs Inhibitors
Jan 29 15
Hybrigenics has extended its partnership with Servier to discover new drugs which inhibit Ubiquitin-Specific Proteases, or USPs. This partnership was initiated in October 2011.
GeNeuro and Servier Sign on Partnership to Develop First Medicine Addressing Causal Factor of Multiple Sclerosis
Dec 2 14
GeNeuro SA announced that it has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated. GNbAC1, a humanized monoclonal antibody, targets MSRV-Env, the envelope protein of MS associated retrovirus, a member of the HERV-W family, the expression of which is usually silent but reactivated and expressed in MS lesions from an early stage in the disease. This protein has been shown to be both pro-inflammatory and an inhibitor of remyelination, the two major drivers of MS pathophysiology. By targeting MSRV-Env, GeNeuro expects to bring to patients a safe, effective treatment that can halt progression of both relapsing-remitting and progressive forms of the disease without hampering the patient’s immune system. GNbAC1 has successfully completed Phase IIa, demonstrating an optimal safety profile and encouraging signs of efficacy on a first small cohort of patients. Under the terms of the agreement, GeNeuro will be responsible for the development of GNbAC1 until completion of Phase IIb, after which Servier can exercise the option to license the product for all markets excluding the USA and Japan. Financial considerations include the payment by Servier to GeNeuro of USD 47 million to finance the completion of Phase IIb. Subsequent to exercising the option agreement, Servier will cover the costs of the Phase III global development program and pay GeNeuro up to USD 408 million in future development and sales milestones, as well as royalties on future sales. Servier will also have the option to take an equity stake in GeNeuro as a minority shareholder in the next 12 months.
Intarcia Therapeutics, Inc., Servier Sign Ex-US Partnership for ITCA 650 in Diabetes
Nov 11 14
Intarcia Therapeutics, Inc. on November 11, 2014 announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650, Intarcia's phase 3 investigational therapy for the treatment of type 2 diabetes. If successful in its remaining phase 3 trials, ITCA 650 would become the world's first and only injection-free GLP-1 agonist given just once or twice yearly in a small, matchstick sized mini-pump placed sub-dermally. A qualified physician, nurse or physician's assistant can place ITCA 650 in a simple five-minute procedure in a doctor's office. Under the agreement, Intarcia is to receive an upfront payment and total potential development, regulatory and sales milestone payments totaling more than $1 billion. Intarcia will also receive ex-U.S./Japan tiered sales-related payments. The parties will also share future global development-related investments for the life cycle management of ITCA 650, including new head-to-head superiority studies against leading diabetes medications, as well as planned novel combination regimens. Intarcia will continue to lead the global ITCA 650 phase 3 pivotal trials, which are on track to support global filings in the first half of 2016. Intarcia also will continue its lead role in the potential registration of ITCA 650 in the U.S., while Servier will seek regulatory approvals outside the U.S. and Japan, with the support of Intarcia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|